DANIEL G WELCH
CIK 1206199 · Chairman, CEO and President · last filed 2026-06-18
DANIEL G WELCH is a Chairman, CEO and President who has filed 118 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for GPCR, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$34.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.0M across reported positions. 55 SEC filings were submitted jointly with INTERMUNE INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.02M
8
118
-$34.94M
Filer Profile
4 UNIVERSITY PLACE
DURHAM, NC 27707
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GPCR | Director | 123,508 | $35.93 | $4.44M | $0 | 5 | 2026-06-18 |
| RARE | Director | 40,441 | $14.50 | $586.4K | $0 | 13 | 2026-05-18 |
| PRTA | Director | — | $8.29 | — | $0 | 4 | 2026-05-15 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 659,947 | $0.01 | $3.4K | $0 | 6 | 2024-05-29 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | -$34.84M | 31 | 2023-12-15 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 8,060 | $19.00 | $153.1K | -$102.1K | 8 | 2020-06-01 |
| AveXis, Inc. (AVXS) Delisted | Director | 0 | — | — | $0 | 4 | 2018-05-15 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 3 | 2015-05-08 |
Recent Filings
118 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | GPCR | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | RARE | Grant (A) | +7,751 | $0 | EDGAR |
| 2026-05-15 | PRTA | Grant (A) | — | $0 | EDGAR |
| 2025-06-25 | GPCR | Grant (A) | — | $0 | EDGAR |
| 2025-05-19 | RARE | Grant (A) | +5,740 | $0 | EDGAR |
| 2025-05-16 | PRTA | Grant (A) | — | $0 | EDGAR |
| 2024-06-27 | GPCR | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | RARE | Grant (A) | +5,345 | $0 | EDGAR |
| 2024-05-29 | Nuvation Bio Inc. (NUVB.WS) Delisted | Exer (M) | +659,947 | $1.11M | EDGAR |
| 2024-05-17 | PRTA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.